Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

PURPOSE: Azacitidine (AZA) is the current standard of care for high-risk (ie, International Prognostic Scoring System high or intermediate 2) myelodysplastic syndrome (MDS), but most patients will experience primary or secondary treatment failure. The outcome of these patients has not yet been descr...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Oncol
Prif Awduron: Prébet, Thomas, Gore, Steven D., Esterni, Benjamin, Gardin, Claude, Itzykson, Raphael, Thepot, Sylvain, Dreyfus, François, Rauzy, Odile Beyne, Recher, Christian, Adès, Lionel, Quesnel, Bruno, Beach, C.L., Fenaux, Pierre, Vey, Norbert
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Clinical Oncology 2011
Pynciau:
ORIGINAL REPORTS
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4859209/
https://ncbi.nlm.nih.gov/pubmed/21788559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.35.8135
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg